Literature DB >> 8229751

Synergistic effects of glyburide and U-37883A, two structurally different vascular ATP-sensitive potassium channel antagonists.

C E Ohrnberger1, S A Khan, K D Meisheri.   

Abstract

Glyburide, a sulfonylurea, and U-37883A, a guanidine (4-Morpholinecarboximidine-N-1-Adamantyl-N' cyclohexylhydrochloride), have been previously characterized as antagonists of the vascular ATP-sensitive K+ channels (KATP). In this report, the in vitro interaction between these two chemically distinct KATP antagonists was investigated using isolated rabbit mesenteric artery. The KATP antagonism was functionally studied as the inhibition of vasodilation produced by various KATP openers as follows: pinacidil (1 microM), minoxidil sulfate (5 microM), cromakalim (0.5 microM) and RP-49356 (1 microM). Glyburide alone produced inhibition in the concentration range of 50 to 500 nM with the glyburide IC50 ranging from 72 to 148 nM. U-37883A alone produced inhibition in the concentration range of 0.5 to 5 microM, with the U-37883A IC50 ranging from 0.78 to 1.4 microM. In the presence of a threshold U-37883A concentration of 0.5 microM, the glyburide inhibition dose-response curve against pinacidil was significantly shifted to the left and the glyburide IC50 was lowered from 72 to 3.9 nM, representing an 18-fold decrease. Similarly, in the presence of a threshold glyburide concentration of 50 nM, the U-37883A inhibition dose-response curve against pinacidil was significantly shifted to the left and the U-37883A IC50 was lowered from 780 to 96 nM, representing an eightfold decrease. Thus, glyburide and U-37883A potentiated each other's effects as KATP blockers. This synergistic interaction between glyburide and U-37883A was observed independently of the pinacidil, cromakalim or minoxidil sulfate used to produce vasodilation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229751

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Inhibition of vascular K(ATP) channels by U-37883A: a comparison with cardiac and skeletal muscle.

Authors:  G C Wellman; R Barrett-Jolley; H Köppel; D Everitt; J M Quayle
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A.

Authors:  H Kovalev; J M Quayle; T Kamishima; D Lodwick
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

Review 3.  ATP-regulated K+ channel in mitochondria: pharmacology and function.

Authors:  A Szewczyk; A Czyz; G Wojcik; L Wojtczak; M J Nalecz
Journal:  J Bioenerg Biomembr       Date:  1996-04       Impact factor: 2.945

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.

Authors:  Yi Cui; Andrew Tinker; Lucie H Clapp
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries.

Authors:  K B Ploug; L J Boni; M Baun; A Hay-Schmidt; J Olesen; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.